ARID1A mutation plus CXCL13 expression act as combinatorial biomarkers to predict responses to immune checkpoint therapy in mUCC
The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
mutation as a combination biomarker in predicting response to ICT in CheckMate275 and IMvigor210. Combination of the two biomarkers in baseline tumor tissues suggested improved OS compared to either single biomarker. Cumulatively, this study revealed that the combination of CXCL13 plus ARID1A may improve prediction capability for patients receiving ICT.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A retrospective analysis identified mutations in ARID1A in tumor tissues and expression of the chemokine CXCL13 as predictive biomarkers for ICT (170).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [170]
In the citing paper
“Importantly, the combination of ARID1A mutation plus CXCL13 showed improved predictive capacity compared with either of the single biomarkers alone (170).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [170]
In the citing paper
“Preclinical studies demonstrated association of ARID1A and CXCL13 with antitumor immunity in mice (170).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [170]
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2020) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21590 · Cited by 20,444
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Mariathasan, S., Turley, S. J., Nickles, D., Castiglioni, A., Yuen, K., Wang, Y., Kadel III, E. E., Koeppen, H., Astarita, J. L., Cubas, R., et al. (2018) · Nature · doi:10.1038/nature25501 · Cited by 5,400
Maftools: efficient and comprehensive analysis of somatic variants in cancer
Mayakonda, A., Lin, D.-C., Assenov, Y., Plass, C., & Koeffler, H. P. (2018) · Genome Research · doi:10.1101/gr.239244.118 · Cited by 4,935 · cited 1×
“The filtered mutation data were analyzed using the R package maftools (32).”
MethodIFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
Ayers, M., Lunceford, J., Nebozhyn, M., Murphy, E., Loboda, A., Kaufman, D. R., Albright, A., Cheng, J. D., Kang, S. P., Shankaran, V., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci91190 · Cited by 3,788
Liu, J., Lichtenberg, T., Hoadley, K. A., Poisson, L. M., Lazar, A. J., Cherniack, A. D., Kovatich, A. J., Benz, C. C., Levine, D. A., Lee, A. V., et al. (2018) · Cell · doi:10.1016/j.cell.2018.02.052 · Cited by 3,725
Self-citationRosenberg, J. E., Hoffman-Censits, J., Powles, T., van der Heijden, M. S., Balar, A. V., Necchi, A., Dawson, N., O'Donnell, P. H., Balmanoukian, A., Loriot, Y., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00561-4 · Cited by 3,669
Self-citationPembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
Bellmunt, J., de Wit, R., Vaughn, D. J., Fradet, Y., Lee, J.-L., Fong, L., Vogelzang, N. J., Climent, M. A., Petrylak, D. P., Choueiri, T. K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613683 · Cited by 3,395
Comprehensive molecular characterization of urothelial bladder carcinoma
Weinstein, J. N., Akbani, R., Broom, B. M., Wang, W., Verhaak, R. G. W., Liu, W., Ju, Z., Motter, T., Peng, B., Ryan, M., et al. (2014) · Nature · doi:10.1038/nature12965 · Cited by 3,142
Self-citationComprehensive molecular characterization of urothelial bladder carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/za09-dk57 · Cited by 2,990
B cells and tertiary lymphoid structures promote immunotherapy response
Helmink, B. A., Reddy, S. M., Gao, J., Zhang, S., Basar, R., Thakur, R., Yizhak, K., Sade-Feldman, M., Blando, J., Han, G., et al. (2020) · Nature · doi:10.1038/s41586-019-1922-8 · Cited by 2,731
Self-citation
Cited by
Items 101–133 of 133
The path forward for T cell engagers in patients with prostate cancer
Subudhi, S. K., Siddiqui, B. A., Zarrabi, K. K., Kelly, W. K., & Drake, C. G. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-013905 · Cited by 2
“80 81 Techniques such as assays of extracellular vesicles—organized packages of nucleic acids, lipids, and proteins—may provide a path forward for longitudinal, non-invasive, combinatorial biomarkers.”
Zhang, X.-M., Zhang, Y., Zhang, Q., Lu, M., Chen, Y., Zhang, X.-Y., & Zhang, P. (2023) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.18063 · Cited by 1
“45 For instance, research by Goswami et al. 46 has demonstrated that when combined with CXCL13 expression, ARID1A mutation can serve as part of a composite biomarker that predicts the response to immune checkpoint therapy in metastatic uroepithelial carcinoma.”
BackgroundSelf-citationPadonou, F., Vanhulst, T., & Fontsa, M. L. (2024) · Current Opinion in Oncology · doi:10.1097/cco.0000000000001015 · Cited by 2
“…aggregates and TLS improved immunotherapy responsiveness [ In many independents cohorts from various cancer types including melanoma, clinically annotated transcriptomic data were used to identify a 12-chemokine CXCL13 expression in their tumor tissue demonstrated overall improve survival [71].”
BackgroundHassouneh, Z., Kim, M. E., Bowman, N., Rao, M. K., Zhang, N., Huang, G., Svatek, R. S., & Mukherjee, N. Z. (2024) · Cancers · doi:10.3390/cancers16193303 · Cited by 7
Chang, Q., Sun, J., Zhao, S., Li, L., Zhang, N., Yan, L., Fan, Y., & Liu, J. (2023) · Aging · doi:10.18632/aging.205261 · Cited by 1
Low, J.-T., Chan, M. W. Y., Shen, C., & Wei, K. (2024) · Molecular Biology Reports · doi:10.1007/s11033-024-09882-y · Cited by 1
“Additionally, their preclinical findings with ARID1A knockdown in MB49 cells show enhanced CXCL10 expression [42].”
Zhu, J., Zhu, X., Su, T., Zhou, H.-Q., Wang, S., & Shi, W. (2025) · Biomedicines · doi:10.3390/biomedicines13051224 · Cited by 1
Vahed, H., Chentoufi, A. A., Prakash, S., Quadiri, A., Karan, S., Lekbach, Y., Omorogieva, E., Patel, S., Tadros, J., Liao, E. J., et al. (2026) · The Journal of Immunology · doi:10.1093/jimmun/vkag017 · Cited by 1
Shapiro, D. D., Nichols, K. D., Lee, M. V., Msaouel, P., Li, Y., Zong, Y., Hu, R., Huang, W., Esbona, K., Kinoshita, T., et al. (2026) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-026-04489-7 · Cited by 1
“While CXCL13 has been implicated in lymphoid architecture and anti-tumor immune responses among other cancer types, its role in ccRCC and relationship to CD8 + T cell recruitment, differentiation, and spatial organization remain poorly defined [18, 21–24].”
Tsunematsu, R., Murai, A., Mizue, Y., Kubo, T., Mariya, T., Morita, R., Murata, K., Kanaseki, T., Tsukahara, T., Hirohashi, Y., et al. (2024) · Cancer Genomics & Proteomics · doi:10.21873/cgp.20460 · Cited by 1
Loss of ARID1A ‘loops’ in STING
Goswami, S., & Sharma, P. (2024) · Trends in Immunology · doi:10.1016/j.it.2024.07.001 · Cited by 1
Self-citationLiu, Z., Zhang, L., Jin, K., Zeng, H., Su, X., Ding, Y., Sun, J., Wu, Y., Liu, H., Zhu, Y., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-0816 · Cited by 2
“ARID1A mutations have been shown to be correlated with immunothera-peutic benefits in urothelial carcinoma, as evidenced in previous studies of the IMvigor210 and CheckMate275 cohorts (19, 23).”
Wang, D., Wang, J., Zhou, D., Wu, Z., Liu, W., Chen, Y., Chen, G., & Zhang, J. (2023) · doi:10.1158/2326-6066.c.6573754 · Cited by 1
Self-citationYolmo, P., Siemens, D. R., & Koti, M. (2023) · European Urology · doi:10.1016/j.eururo.2023.12.003 · Cited by 1
Hamade, A., Li, D., Tyryshkin, K., Xu, M., Chenard, S. W., Conseil, G., Yolmo, P., Siemens, D. R., & Koti, M. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.09.10.459788
Sharma, P., Anandhan, S., Siddiqui, B. A., Goswami, S., Subudhi, S. K., Gao, J., Peggs, K. S., Quezada, S. A., & Allison, J. P. (2022) · Wiley eBooks · doi:10.1002/9781119000822.hfcm068.pub2
Self-citationWang, D., Wang, J., Zhou, D., Wu, Z., Liu, W., Chen, Y., Chen, G., & Zhang, J. (2023) · doi:10.1158/2326-6066.c.6573754.v1
Self-citationGuo, Y. A., Kulshrestha, T., Chang, M. M., Kassam, I., Revkov, E., Rizzetto, S., Tan, A. C., Tan, D. S. W., Tan, I. B., & Skanderup, A. J. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.07.30.551135
CXCL10 could be a prognostic and immunological biomarker in bladder cancerPreprint
殷, 涛., mou, S., Zhang, H., Dong, Y., Yan, B., Huang, W., Liu, Y., & Mei, H. (2024) · Research Square · doi:10.21203/rs.3.rs-3921289/v1
Wu, J., Jiang, S., Shen, Q., & Gong, H. (2025) · Oncology Letters · doi:10.3892/ol.2025.15008 · Cited by 1
Constructing a Predictive Model for PD-1 Blockade Therapy in Pan-Cancer Based on Machine LearningPreprint
Li, H., Li, S., Xiong, L., Yang, M., Dai, W., Luo, X., Liu, S., Xiao, D., Ning, B.-Y., Liu, Y., et al. (2025) · Research Square · doi:10.21203/rs.3.rs-6317412/v1
Self-citationGuevara, D. E., Assaad, M. A., Manohar, J., Sigouros, M., Otilano, J. R., King, A. S., Fedorov, C., Butusova, A., Aghajanyan, A., Channov, V., et al. (2025) · Academia oncology. · doi:10.20935/acadonco7774
Hamade, A., Li, D., Tyryshkin, K., Xu, M., Conseil, G., Yolmo, P., Hamilton, J., Chenard, S., Robert Siemens, D., & Koti, M. (2022) · Figshare · doi:10.6084/m9.figshare.19704021
Hamade, A., Li, D., Tyryshkin, K., Xu, M., Conseil, G., Yolmo, P., Hamilton, J., Chenard, S., Robert Siemens, D., & Koti, M. (2022) · Figshare · doi:10.6084/m9.figshare.19704006
Hamade, A., Li, D., Tyryshkin, K., Xu, M., Conseil, G., Yolmo, P., Hamilton, J., Chenard, S., Robert Siemens, D., & Koti, M. (2022) · Figshare · doi:10.6084/m9.figshare.19704000
Tang, Z., Chi, H., Zhao, W., Wang, R., Yang, Y., Xu, Z., Ding, Z., Chen, K., Lu, J., Hu, S., et al. (2026) · Discover Oncology · doi:10.1007/s12672-026-04780-0
“The researchers also concluded that baseline CXCL13 expression combined with ARID1A mutation can serve as a predictive marker of therapeutic efficacy in patients undergoing ICIs [66].”
Gut microbiota-related biomarkers in immuno-oncology
Silva, C. A. C. (2023) · theses.fr (ABES) · doi:10.70675/9022496ez0bbbz4f94z9760z4ae0a6ee5e7a
Groeneveld, C. S. (2023) · theses.fr (ABES) · doi:10.70675/10c68a9dz9fcaz441ez9760zd2be90dbb9d0
Microscopie électronique à balayage appliquée en microbiologie clinique : le grand retour !
Haddad, G. (2022) · theses.fr (ABES) · doi:10.70675/0fdc30ffz897az4e11z8b14z2ad50de7751c
Rouanne, M., Chen, N., Mariuzza, D. L., Yang, Z., Li, F., Santos, K. D. L., Savage, T. M., Vincent, R. L., Mendelsohn, C. L., Danino, T., et al. (2026) · Science Translational Medicine · doi:10.1126/scitranslmed.adv7600 · Cited by 3
Botta, G. P., Edwards, W. F., Nishizaki, D., Hargreaves, D. C., Kato, S., & Kurzrock, R. (2026) · iScience · doi:10.1016/j.isci.2026.116772
CXCR5 regulates CD8+/GZMB+ T cell infiltration and apoptotic signaling in breast cancer
Feng, W., Yan, J., Gong, X., Hu, J.-D., Jin, M.-L., Ma, C.-H., & Li, F.-G. (2026) · iScience · doi:10.1016/j.isci.2026.117874
Kumari, H., Chou, C., Lee, Y.-T., Shen, C.-H., & Chan, M. W. Y. (2026) · Experimental Biology and Medicine · doi:10.3389/ebm.2026.11373
Metadata
- Authors
- Goswami, S., Chen, Y., Anandhan, S., Szabo, P. M., Basu, S., Blando, J. M., Liu, W., Zhang, J., Natarajan, S. M., Xiong, L., Guan, B., Yadav, S. S., Saci, A., Allison, J. P., Galsky, M. D., & Sharma, P.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Department of Translational Medicine, Bristol Myers Squibb, Princeton, NJ 08540, USA.
- Bristol-Myers Squibb (United States) (US)
- Tisch Cancer Institute (US)
- Corresponding author
- Sharma, Padmanee
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2020-06-17
- Volume
- 12
- Issue
- 548
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W3036281565
- Cited by
- 133
- References
- 36
- Citations by year
- 2026: 10 · 2025: 18 · 2024: 21 · 2023: 24 · 2022: 26 · 2021: 29 · 2020: 5
- FWCI
- 7.58
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Parker Institute for Cancer Immunotherapy
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Surgery › Bladder and Urothelial Cancer Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- ARID1A mutation, immune checkpoint inhibitors, biomarkers, metastatic urothelial carcinoma, treatment response prediction, overall survival, IMvigor210
- MeSH terms
- Animals, Urinary Bladder Neoplasms, DNA-Binding Proteins, Humans, Mutation, Transcription Factors, Biomarkers, Tumor, Biomarkers, Mice, Chemokine CXCL13, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.